NASDAQ : MLYS

Mineralys Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 18.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.61B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Details

NameMineralys Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees76
Founded2019
Ipo Date2023-02-10
CeoJon Congleton
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price16.00
IsinUS6031701013
Cusip603170101
Cik1933414
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Jon CongletonPresident, Chief Executive Officer and Director
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.Founder and Executive Director
Adam Scott LevyChief Financial Officer and Secretary
Jeffrey A. Munsie J.D.Chief Legal Officer
Dr. Robert McKean Ph.D.Senior Vice President of CMC
Danielle MahoneySenior Vice President of Quality Assurance
Jessica IbbitsonExecutive Vice President of Operations
Eric J. Warren R.Ph.Chief Commercial Officer
Michael Tortorici Ph.D., Pharm.D.Senior Vice President of Translational Medicine
Dr. James J. Ferguson III, FACC, M.D.Chief Medical Officer

Contact

Address150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087, United States
Phone888 378 6240
Websitehttps://mineralystx.com